Cite
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.
MLA
Persson, Frederik, et al. “Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.” Diabetes Care, vol. 44, no. 8, Aug. 2021, pp. 1894–97. EBSCOhost, https://doi.org/10.2337/dc21-0300.
APA
Persson, F., Rossing, P., Vart, P., Chertow, G. M., Hou, F. F., Jongs, N., McMurray, J. J. V., Correa-Rotter, R., Bajaj, H. S., Stefansson, B. V., Toto, R. D., Langkilde, A. M., Wheeler, D. C., Heerspink, H. J. L., & DAPA-CKD Trial Committees and Investigators. (2021). Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. Diabetes Care, 44(8), 1894–1897. https://doi.org/10.2337/dc21-0300
Chicago
Persson, Frederik, Peter Rossing, Priya Vart, Glenn M. Chertow, Fan Fan Hou, Niels Jongs, John J.V. McMurray, et al. 2021. “Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.” Diabetes Care 44 (8): 1894–97. doi:10.2337/dc21-0300.